These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37121698)

  • 1. Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.
    Okuyama R
    Biol Pharm Bull; 2023; 46(5):718-724. PubMed ID: 37121698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
    Nakata M; Tang W
    Drug Discov Ther; 2008 Oct; 2(5):262-3. PubMed ID: 22504718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chapter 1. A contemporary history of the Japanese pharmaceutical industry (1980-2010). A contemporary history of the Japanese Pharmaceutical Industry (1980-2010) Task Force].
    Yakushigaku Zasshi; 2014; 49(1):18-38. PubMed ID: 25272635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chapter 5. The internationalization of the Japanese pharmaceutical industry (1980-2010)].
    Yongue JS
    Yakushigaku Zasshi; 2014; 49(1):77-83. PubMed ID: 25272639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chapter 2. Transitions in drug-discovery technology and drug-development in Japan (1980-2010)].
    Sakakibara N; Yoshioka R; Matsumoto K
    Yakushigaku Zasshi; 2014; 49(1):39-49. PubMed ID: 25272636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconsidering Japan's underperformance in pharmaceuticals: evidence from Japan's anticancer drug sector.
    Umemura M
    Enterp Soc; 2010; 11(3):560-93. PubMed ID: 20821877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
    Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
    Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [International Partnership for Therapeutic Drug Development of NTDs by DNDi].
    Yamada H; Hirabayashi F; Brünger C
    Yakugaku Zasshi; 2016; 136(2):213-22. PubMed ID: 26831796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System.
    Shibata S; Uemura R; Suzuki T
    Ther Innov Regul Sci; 2016 Nov; 50(6):751-758. PubMed ID: 30231734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of new companies for drug discovery: origins of a decade of new drugs.
    Kneller R
    Nat Rev Drug Discov; 2010 Nov; 9(11):867-82. PubMed ID: 21031002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chapter 4. Transitions in pharmaceutical market, production and sales in Japan (1980-2010)].
    Yoshioka R; Matsumoto K
    Yakushigaku Zasshi; 2014; 49(1):64-76. PubMed ID: 25272638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries.
    Yashiro K; Lim Y; Sengoku S; Kodama K
    Drug Discov Today; 2023 Mar; 28(3):103483. PubMed ID: 36584874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.